Medscape

FDA OKs Guselkumab for Crohn’s Disease

The US Food and Drug Administration (FDA) approved guselkumab (Tremfya, Johnson & Johnson) for the treatment of adults with moderate to severe active Crohn’s disease (CD). The approval marks the ...
Healio

Guselkumab exhibits ‘good efficacy’ in perianal fistulizing Crohn’s disease

Please provide your email address to receive an email when new articles are posted on . More than a quarter of patients who received guselkumab induction and maintenance therapy achieved combined ...
Delaware County Daily Times

New Phase 3 Data Show First-in-Class TREMFYA(R) (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis ...

In addition, results showed 56 percent of TREMFYA q4w patients and 55 percent of TREMFYA q8w patients achieved at least 50 percent improvement in ACR score (utilizing NRI). 2 Among patients who had ...
Healio

Early benefit with guselkumab predicts lower psoriatic arthritis progression at 2 years

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with joint improvement by week 8 had lower ...
Morningstar

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease

TREMFYA met the primary endpoint of combined fistula remission at Week 24, defined as complete closure of all external fistula openings with no drainage, without development of new fistulas and no ...